Medtronic/Tandem Patent Agreement Paves Way For Diabetes Product Development
Tandem Diabetes Care and Medtronic have signed a patent cross-license agreement that paves the way for joint development of future diabetes products and services while avoiding potential legal disagreements.
You may also be interested in...
Three major insulin pump developers are gearing up to introduce next-generation devices over the coming year, but COVID-19 continues to create uncertainties.
This week's Device Week podcast covers the recent American Diabetes Association conference, which was held online for the first time. The major diabetes device makers – Abbott, Medtronic and Dexcom – used the meeting to announce new clinical data and explain their diabetes product pipeline to customers and investors.
After announcing positive results at the American Diabetes Association conference and an expanded FDA approval for its insulin pump delivery system, Tandem Diabetes Care’s CEO outlines its path forward.